Results 11 to 20 of about 11,782,455 (235)
Statins in Non-alcoholic Steatohepatitis [PDF]
Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH).
Jose D. Torres-Peña +5 more
doaj +5 more sources
Fructose and Non-Alcoholic Steatohepatitis [PDF]
Background: The excessive consumption of free sugars is mainly responsible for the high prevalence of obesity and metabolic syndrome in industrialized countries.
Elke Roeb, Ralf Weiskirchen
doaj +4 more sources
The interplay between western diet and gut microbiota drives the development of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis.
Shi-You Chen +2 more
exaly +2 more sources
Therapies for non-alcoholic steatohepatitis
Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj +2 more sources
Myotonic dystrophy is a multisystemic disorder characterized by repeat expansion mutations of the dystrophia myotonica protein kinase (DMPK) gene resulting in a defective muscular insulin receptor and insulin resistance.
Rishi R. Bhardwaj, Andrea Duchini
doaj +2 more sources
Non-alcoholic Steatohepatitis: An Overview
Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of fat-induced liver injury, ranging from mild steatosis to cirrhosis and liver failure.
Allison Shifflet, George Y. Wu
doaj +3 more sources
Progress on cholesterol metabolism and non-alcoholic steatohepatitis [PDF]
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD). Cholesterol is an essential substance for biological process.
LI Xiao-xiao, SHU Xiang-bing, ZHANG Li
doaj +2 more sources
Endocannabinoids and non-alcoholic steatohepatitis
Non alcoholic steatohepatitis (NASH) has gained a lot of attention recently due to the increased prevalence of diabetes, obesity, and hyperlipedemia. The endogenous compounds, endocannabinoids (ECBs), bind to the same receptors as tetrahydrocannabinol ...
Helmy Ahmed
doaj +3 more sources
Recurrent and de novo non-alcoholic steatohepatitis following orthotopic liver transplantation [PDF]
Background — Non-alcoholic steatohepatitis was coined in 1980 to describe pathological and clinical features of non-alcoholic disease associated with pathological features, commonly seen in alcoholic-liver disease itself.
Raquel F. Liermann GARCIA +5 more
doaj +1 more source
Alcoholic and non-alcoholic steatohepatitis [PDF]
This paper is based upon the “Charles Lieber Satellite Symposia” organized by Manuela G. Neuman at the Research Society on Alcoholism (RSA) Annual Meetings, 2013 and 2014. The present review includes pre-clinical, translational and clinical research that characterize alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH). In addition, a
Manuela G, Neuman +24 more
openaire +2 more sources

